EMERGENT BIOSOLUTIONS INC

NYSE: EBS (Emergent BioSolutions Inc.)

Last update: 19 Jan, 3:57PM

10.99

0.04 (0.37%)

Previous Close 10.95
Open 11.01
Volume 1,622,680
Avg. Volume (3M) 1,080,090
Market Cap 586,328,576
Price / Earnings (TTM) 8.33
Price / Earnings (Forward) 3.04
Price / Sales 0.910
Price / Book 1.10
52 Weeks Range
4.02 (-63%) — 14.06 (27%)
Earnings Date 29 Oct 2025
Profit Margin -13.63%
Operating Margin (TTM) 22.68%
Diluted EPS (TTM) -2.58
Quarterly Revenue Growth (YOY) -26.00%
Quarterly Earnings Growth (YOY) 655.60%
Total Debt/Equity (MRQ) 121.71%
Current Ratio (MRQ) 6.32
Operating Cash Flow (TTM) 110.10 M
Levered Free Cash Flow (TTM) 91.12 M
Return on Assets (TTM) -1.61%
Return on Equity (TTM) -21.63%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Bullish
Drug Manufacturers - Specialty & Generic (Global) Mixed Bullish
Stock Emergent BioSolutions Inc. Mixed Bullish

AIStockmoo Score

-0.9
Analyst Consensus 0.5
Insider Activity NA
Price Volatility -4.5
Technical Moving Averages 1.0
Technical Oscillators -0.5
Average -0.88

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
EBS 586 M - 8.33 1.10
AMRX 4 B - 1,333.00 -
BHC 3 B - 7.63 -
PRGO 2 B 2.19% - 0.430
TAK 56 B 4.61% 77.03 1.08
HLN 48 B 1.08% 23.51 2.08

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Small Value
% Held by Insiders 2.83%
% Held by Institutions 67.20%
52 Weeks Range
4.02 (-63%) — 14.06 (27%)
Median 15.00 (36.49%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 16 Dec 2025 15.00 (36.49%) Buy 12.19

No data within this time range.

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria